What they do: Pharmaceutical Preparations · Exchange: Nasdaq · Employees: 12
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia. (via Yahoo Finance)
No quarterly earnings trend available (foreign private issuer, non-10-Q filer, or stale/no recent XBRL data).
Insiders hold: 18.27% · Institutions hold: 0.00%
| Trade date | Filed | Name | Role | Action | Shares | Price | Value | Stock since |
|---|---|---|---|---|---|---|---|---|
| 2026-10-13 | 2026-10-13 | BERGER FRANKLIN M | Director | CONVERSION | 12,517 | — | — | +5.0% |
| 2026-10-13 | 2026-10-13 | BERGER FRANKLIN M | Director | BOUGHT | 10,000 | $12.00 | $120K | +5.0% |
| 2026-10-13 | 2026-10-13 | Keller Eric L. | CHIEF EXECUTIVE OFFICER | CONVERSION | 9,662 | — | — | +5.0% |
| 2026-10-13 | 2026-10-13 | Keller Eric L. | CHIEF EXECUTIVE OFFICER | CONVERSION | 31,368 | — | — | +5.0% |
| 2026-10-13 | 2026-10-13 | Keller Eric L. | CHIEF EXECUTIVE OFFICER | BOUGHT | 20,800 | $12.00 | $250K | +5.0% |